BLUEROCK THERAPEUTICS
BLUEROCK THERAPEUTICS logo

BlueRock Therapeutics LP is a clinical stage cell therapy company focused on creating cellular medicines to reverse devastating diseases. The company's cell+gene platform is harnessing the power of cells to create a pipeline of new medicines for patients suffering from neurological, cardiovascular, immunological, and ophthalmic diseases. BlueRock's lead clinical program, bemdaneprocel, (BRT-DA01) is in Phase 1 clinical trials for Parkinson’s disease. BlueRock Therapeutics was founded in 2016 by Versant Ventures and Bayer AG and became a wholly owned, independently operated subsidiary of Bayer AG in late 2019 as a cornerstone of its newly formed Cell & Gene Therapy Platform.

Disclaimer : All logos and trademarks on this website are the property of their respective owners. The information on this website is not a medical or investment related advice. The information about the company might not reflect the most current or accurate information. Please refer to the company's respective website for the most accurate information.

© 2023-24 DxMultiomics. All rights reserved.